20 percent more patients were treated with proton therapy in 2019

An individual eye shield is made for each patient to protect the surrounding tissue from the proton beam.

An individual eye shield is made for each patient to protect the surrounding tissue from the proton beam. © HZB

Number of patients who received the proton therapy offered jointly by Charité and HZB.

Number of patients who received the proton therapy offered jointly by Charité and HZB. © HZB/J. Politt

For more than 20 years, Charité - Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have jointly offered the irradiation of eye tumors with protons. In 2019, more patients were treated in Berlin-Wannsee than ever before. 276 patients - 20 percent more than in the previous year - underwent proton therapy. The treatment is specialized in choroidal melanomas of the eye. The proton accelerator at HZB is the only treatment facility for this disease in Germany. 

500 to 600 people in Germany are affected by a malignant choroidal melanoma every year. In 97 percent of cases, the tumour can be completely destroyed by irradiation with protons. In most cases, not only the eye but also the vision can be maintained to a satisfactory degree. "The energy of the proton beam can be adjusted in such a way that practically only the tumor receives the radiation. Since the protons have a straight trajectory, the lateral scattering is much less than with X-rays," explains Dr. Jens Heufelder, the senior medical physicist at Charité - Universitätsmedizin Berlin. The protons effectively destroy the tumor, while the surrounding healthy tissue is largely spared.

To cope with the increase in patients in 2019, treatment operations at the proton accelerator have been extended to 12 hours. Approximately 45 percent of the patients came from the Berlin-Brandenburg region, the other patients came from other German states and other European countries (approximately 8 percent). The youngest patient who received proton therapy at HZB in 2019 was 8 years old, the oldest patient 96 years old. The average age was 61 years.

Since 1998, more than 3,700 patients have been treated with protons from the HZB accelerator. "The success of proton therapy is based on the collaboration between ophthalmologists, medical physicists and accelerator experts. As a result, the therapy has been continuously improved for the benefit of patients over the past few years", explains Prof. Dr. Andrea Denker, head of proton therapy at HZB. 

(sz)

You might also be interested in

  • Humboldt Fellow Alexander Gray comes to HZB
    News
    12.08.2022
    Humboldt Fellow Alexander Gray comes to HZB
    Alexander Gray from Temple University in Philadelphia, USA, is working with HZB physicist Florian Kronast to investigate novel 2D quantum materials at BESSY II. With the fellowship from the Alexander von Humboldt Foundation, he can now deepen this cooperation. At BESSY II, he wants to further develop depth-resolved X-ray microscopic and spectroscopic methods in order to investigate 2D quantum materials and devices for new information technologies even more thoroughly.
  • Green hydrogen: Nanostructured nickel silicide shines as a catalyst
    Science Highlight
    11.08.2022
    Green hydrogen: Nanostructured nickel silicide shines as a catalyst
    Electrical energy from wind or sun can be stored as chemical energy in hydrogen, an excellent fuel and energy carrier. The prerequisite for this, however, is efficient electrolysis of water with inexpensive catalysts. For the oxygen evolution reaction at the anode, nanostructured nickel silicide now promises a significant increase in efficiency. This was demonstrated by a group from the HZB, Technical University of Berlin and the Freie Universität Berlin as part of the CatLab research platform with measurements among others at BESSY II.
  • RBB Abendschau on visit at CatLab
    News
    01.08.2022
    RBB Abendschau on visit at CatLab
    CatLab got a visit from the rbb Abendschau.
    Under the title "Der Weg weg vom Erdgas" (The way away from natural gas), the programme was broadcast on Sunday, 31st July in the rbb Abendschau and will be available in the rbb media library for 7 days.